Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
France Targets Shein, Temu With Fast-Fashion Fees 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Add as a preferred source on Google
SAN DIEGO, March 09, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces it will host its annual Cambridge UK symposium on Thursday, March 15th at The Cambridge Building, Babraham Research Campus.
The scientific symposium, entitled “Perspectives on Oncology Drug Discovery; Immuno-Oncology and the Next Generation”, will bring together some of the most influential names in preclinical oncology drug discovery. Distinguished speakers from various multinational pharmaceutical and European biotech companies will present data describing how their latest research efforts provide innovative, unique solutions to advance immunotherapeutics and preclinical pharmacology evaluation.
“I look forward to welcoming the scientific community to our 4th annual Cambridge UK Symposium”, said Dr. Sebastian Dempe, CrownBio’s Executive Director UK and European business unit. “Immuno-oncology and its preclinical modeling has become a tremendously important focus in cancer research. This year’s symposium promises to provide an excellent opportunity for networking and scientific discussions around the latest advances in immuno-oncology research.”
Register to attend the symposium here, http://bit.ly/CrownBio_Cambridge18
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
